Skip to content

Evidence-based evaluation research of TCM nasal spray which have the function of replenishing qi and activating blood in the treatment of allergic rhinitis

Efficacy and safety of Modified Yupingfeng Nasal Spray in Controlling the Recurrence of Persistent and Moderate-Severe Allergic Rhinitis: Study Protocol for a Multicentre, Open-Label, Randomized, and Parallel-Arm Trial

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2100004917
Enrollment
Unknown
Registered
2021-06-07
Start date
2021-09-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

allergic rhinitis

Interventions

Sponsors

The Teaching Hospital of Chengdu University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Those who meet the above diagnostic standards; 2. Patients with a positive skin prick test of grade 2 or above; 3. Aged 18 to 65 years without gender restriction; 4. Not received any medication for AR in the past two weeks; 5. Agree to participate in this test and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Patients combined with severe nasal septal deviation, chronic nasal-sinusitis, bronchial asthma, nasal polyps and other diseases; 2. With heart, liver and kidney disorder or autoimmune diseases; 3. combined with mental illness, mental disorders and unable to cooperate to complete the test; 4. Patients during pregnancy, lactation, or during pregnancy preparation; 5. Patient is allergic to the composition of the clinical trial drug; 6. Patients who had received glucocorticoids, leukotriene receptor blockers, antihistamines, or anti-inflammatory drugs within two weeks; 7. Patients with skin pathological changes at the site of the skin prick test; 8. Patients who are currently and have previously participated in specific immunotherapy; 9. Patients who have participated in other clinical studies in the past two months.

Design outcomes

Primary

MeasureTime frame
Rhinitis control test;Recurrence rate;

Secondary

MeasureTime frame
Spleen Qi Deficiency Systemic Symptoms Scoring Table;Toll-like receptor 4;Myeloid differentiation factor;Human chemokine receptor 7;Duration of medication (days);Visual analog scale;Nuclear factor-??;Lung Qi Deficiency Systemic Symptoms Scoring Table;Rhinoconjunctivitis quality of life scale;Total score for eye symptoms;Interferon gamma;TIR domain adaptor protein;Nasal endoscopic results;Interleukin 4;Platelet activating factor;Carbon monoxide;Heme oxygenase 1;Chinese Medicine Physique Classification and Judgment Table;Human chemokine receptor 6;Total score for nasal symptoms;Tumor Necrosis Factor Alpha;

Countries

China

Contacts

Public ContactTian Li

The Teaching Hospital of Chengdu University of Traditional Chinese Medicine

ctcmdan@stu.cdutcm.edu.cn+86 18980880129

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026